Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Future Directions in Gastric Cancer Treatment

November 17th 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Treatment Considerations With TROP2-Targeted Therapy

November 17th 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Unresectable HER2– Gastric/GEJ Adenocarcinoma

November 16th 2023

The FDA has approved pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer

November 14th 2023

China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.

PD-L1 IHC 22C3 pharmDx Gets Green Light From FDA for Determining Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

November 14th 2023

The FDA has approved the PD-L1 IHC 22C3 pharmDx diagnostic tool to aid clinicians in identifying patients with gastric or gastroesophageal junction adenocarcinoma who may be eligible for treatment with the PD-1 inhibitor pembrolizumab.

Frontline Pembrolizumab Plus Chemo Approaches EU Approval for Biliary Tract Cancer

November 10th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) combined with gemcitabine and cisplatin in the frontline treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer

TROP2-Targeting Antibody-Drug Conjugates

November 10th 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies

November 10th 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

Unique Molecular Profiles of Biliary Tract Cancers Drive Continued Development of Targeted Therapies

November 9th 2023

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

November 9th 2023

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

FDA Restricts Approval for Pembrolizumab Plus Trastuzumab and Chemo to Advanced PD-L1+ Gastric/GEJ Cancer

November 9th 2023

The FDA has updated the current indication for pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma to those whose tumors express PD-L1 with a CPS of 1 or more.

CMG901 Elicits Responses in CLDN18.2-Expressing Gastric/GEJ Cancer

November 7th 2023

CMG901 induced responses with a manageable toxicity profile in patients with CLDN18.2-positive gastric or gastroesophageal junction cancer, according to updated data from the dose-expansion phase of the phase 1 KYM901 study.

Domvanalimab Plus Zimberelimab and Chemotherapy Elicits Responses in Advanced Gastric/GEJ Adenocarcinoma

November 7th 2023

The combination of domvanalimab, zimberelimab, and FOLFOX elicited responses in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, irrespective of PD-L1 status.

Frontline Cadonilimab Plus Chemotherapy Improves OS in Advanced Gastric/GEJ Adenocarcinoma

November 7th 2023

First-line treatment with the PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxaliplatin and capecitabine led to a statistically significant improvement in overall survival vs placebo plus oxaliplatin and capecitabine in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, meeting the primary end point of the phase 3 AK104-302 trial.

FDA Accepts IND for Novel CDH17-Targeted CAR T-Cell Therapy for Advanced Gastrointestinal Cancers

November 6th 2023

The FDA has cleared the investigational new drug application for CHM 2101, a novel CDH17-targeted CAR T-cell therapy, for the treatment of patients with gastrointestinal cancers.

Assessing the Promise of AI in Oncology: Potential for Precision Medicine

November 6th 2023

In this second episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools may be leveraged in the oncology field to provide personalized care.

Managing T-DXd Toxicities in Gastric Cancer

November 3rd 2023

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

Gastric Cancer Treatment: T-DXd

November 3rd 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

FDA Approves Pembrolizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

November 1st 2023

The FDA has approved pembrolizumab (Keytruda) plus gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.

FDA Lifts Clinical Hold on Phase 1 Trial Evaluating XMT-2056 in HER2-Expressing Solid Tumors

October 31st 2023

The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.